摘要

Objectives: To demonstrate the clinical efficacy of High-Intensity Electromagnetic Stimulation (HITS™) as a non-invasive therapeutic strategy to counteract inflammaging and muscle mass loss associated with GLP-1 receptor agonist–induced weight reduction. Introduction: GLP-1 receptor agonists have revolutionized the management of obesity by inducing significant weight loss and improving metabolic control. However, rapid weight reduction is frequently associated with substantial loss of lean mass, raising concerns about sarcopenia, functional decline, and accelerated senescence. Given that skeletal muscle is a central metabolic and endocrine organ, preserving muscle mass has become a critical challenge in the era of GLP-1 therapies. Materials / method: This presentation integrates evolutionary biology, metabolic physiology, and clinical evidence to analyze the mechanisms of muscle loss associated with GLP-1–induced weight reduction. In addition, data from a pilot clinical experience using High-Intensity Tesla Magnetic Stimulation (HITS™) were reviewed. Sixteen patients with inflammatory and metabolic alterations underwent a six-week HITS™ protocol targeting large muscle groups, with assessment of clinical symptoms and metabolic-inflammatory biomarkers. Results: GLP-1–associated weight loss was shown to include a clinically relevant reduction in skeletal muscle mass. HITS™ therapy was well tolerated and associated with improvements in fatigue, insomnia, libido, insulin sensitivity, and reductions in pro-inflammatory markers such as TNF-α, suggesting beneficial effects on muscle activation and systemic inflammation. Conclusion: In the era of GLP-1 therapies, muscle preservation should be considered a cornerstone of obesity and longevity medicine. Non-invasive technologies capable of restoring muscle activity may play a key role in preventing sarcopenia, supporting metabolic health, and promoting healthy aging.